International audienceChlamydomonas reinhardtii is a green unicellular eukaryotic model organism for studying relevant biological and biotechnological questions. The availability of genomic resources and the growing interest in C. reinhardtii as an emerging cell factory for the industrial production of biopharmaceuticals require an in-depth analysis of protein N-glycosylation in this organism. Accordingly, we used a comprehensive approach including genomic, glycomic, and glycoproteomic techniques to unravel the N-glycosylation pathway of C. reinhardtii. Using mass-spectrometry-based approaches, we found that both endogenous soluble and membrane-bound proteins carry predominantly oligomannosides ranging from Man-2 to Man-5. In addition, mino...
At present, only little is known about the enzymatic machinery required for N-glycosylation in Chlam...
AbstractGreen algae have a great potential as biofactories for the production of proteins. Chlamydom...
Currently, more than 70% of the commercialized biopharmaceuticals are glycoproteins. The high produc...
International audienceChlamydomonas reinhardtii is a green unicellular eukaryotic model organism for...
International audienceChlamydomonas reinhardtii is a green unicellular eukaryotic model organism for...
Green algae have a great potential as biofactories for the production of proteins. Chlamydomonas rei...
AbstractGreen algae have a great potential as biofactories for the production of proteins. Chlamydom...
Eukaryotic N-glycosylation pathways are dependent of N-acetylglucosaminyltransferase I (GnTI), a key...
International audienceEukaryotic N-glycosylation pathways are dependent of N-acetylglucosaminyltrans...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
International audienceEukaryotic N-glycosylation pathways are dependent of N-acetylglucosaminyltrans...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
At present, only little is known about the enzymatic machinery required for N-glycosylation in Chlam...
AbstractGreen algae have a great potential as biofactories for the production of proteins. Chlamydom...
Currently, more than 70% of the commercialized biopharmaceuticals are glycoproteins. The high produc...
International audienceChlamydomonas reinhardtii is a green unicellular eukaryotic model organism for...
International audienceChlamydomonas reinhardtii is a green unicellular eukaryotic model organism for...
Green algae have a great potential as biofactories for the production of proteins. Chlamydomonas rei...
AbstractGreen algae have a great potential as biofactories for the production of proteins. Chlamydom...
Eukaryotic N-glycosylation pathways are dependent of N-acetylglucosaminyltransferase I (GnTI), a key...
International audienceEukaryotic N-glycosylation pathways are dependent of N-acetylglucosaminyltrans...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
International audienceEukaryotic N-glycosylation pathways are dependent of N-acetylglucosaminyltrans...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
International audienceIn eukaryots the protein N-glycosylation processes starts in the endoplasmic r...
At present, only little is known about the enzymatic machinery required for N-glycosylation in Chlam...
AbstractGreen algae have a great potential as biofactories for the production of proteins. Chlamydom...
Currently, more than 70% of the commercialized biopharmaceuticals are glycoproteins. The high produc...